Which company does Fam-trastuzumab deruxtecan-nxki come from?

Fam-trastuzumab deruxtecan-nxki is a specially designed HER2-directed antibody-drug conjugate (ADC) using Daiichi Sankyo's proprietaryDXd ADC technology is designed to be the leading antibody-drug conjugate in Daiichi Sankyo's oncology portfolio and the most advanced program in AstraZeneca's ADC scientific platform, and is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

Trastuzumab, a conjugate mainly antibody HER2 and a topoisomerase inhibitor, is used to treat breast cancer, gastric cancer and non-small cell lung cancer with specific HER2 gene mutations. Trastuzumab slows the growth and progression of cancer by blocking the HER2 receptor on cancer cells to prevent them from multiplying, and then its second action is to destroy or kill the cancer cells. Trastuzumab is a combination of two anti-cancer drugs, a monoclonal antibody (fam-trastuzumab) and a chemotherapy drug (topoisomeraseI inhibitor). The U.S. Food and Drug Administration (FDA) approved trastuzumab for the first time on December 20, 2019.

Trastuzumab is a new type of injectable anti-cancer drug. The original drug has been launched in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear, and its purchase method is difficult. The Hong Kong version of TrastuzumabSpecifications100mg may cost more than 10,000 yuan per box, and the Hong Kong original versionTrastuzumabOriginal drug specificationsThe price of 100mg per box may be around 15,000 yuan (the price may fluctuate due to exchange rate effects). The drug ingredients of the two are basically the same. There is currently no generic drug of Trastuzumab produced and launched. For more specific prices and drug information, please consult the medical consultant of the drug.